Compounded semaglutide

Semaglutide belongs to the class of medicines known as GLP-1 receptor agonists, and acts on the GLP-1 receptor pathway.

What you are prescribed here is a compounded preparation: made to a prescription rather than manufactured and packaged as a branded product.

FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, and that compounded drugs are not FDA approved — the agency does not review them for safety, effectiveness or quality before they are marketed. U.S. Food and Drug Administration, 2026-09-01

As of 31 May 2026 FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and it says these are likely underreported, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to report them. FDA also says it is not always possible to determine whether an adverse event resulted directly from use of the drug, or whether other factors contributed to it. U.S. Food and Drug Administration, 2026-09-01

FDA says it is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that carry false information on the product label: in some cases the compounding pharmacies named on the label do not exist, and in others the label names a licensed pharmacy that, on the information FDA has gathered, did not compound the product. One reported adverse event involved a product labelled as compounded tirzepatide from a pharmacy that did not actually compound it. U.S. Food and Drug Administration, 2026-09-01

FDA says it has received complaints that certain compounded GLP-1 drugs have arrived warm or with inadequate ice packs to keep the drug at recommended storage temperatures. U.S. Food and Drug Administration, 2026-09-01

FDA says it is aware that compounded GLP-1 medications may be dispensed in vials containing multiple doses for a patient to self-administer, and that vials containing multiple doses of sterile medication carry an increased risk of contamination more than 28 days after they are first used. U.S. Food and Drug Administration, 2026-09-01

FDA has established a green list import alert to help stop GLP-1 active pharmaceutical ingredients that have potential quality concerns from entering the U.S. supply chain, which it says will help protect consumers from receiving poor-quality compounded drugs containing foreign-made ingredients that may be manufactured without appropriate controls to assure quality. U.S. Food and Drug Administration, 2026-09-01

FDA advises obtaining a prescription from a doctor and filling it at a state-licensed pharmacy, and names seven warning signs for a telehealth seller: claims that the compounded drug is the same as an FDA-approved drug; medicine offered at deep discounts or at prices that seem too good to be true; medicine that looks different from what you have previously received or from what was pictured, or that arrives in packaging that is broken or damaged or lacks instructions for use; no screening and prescription by a licensed doctor before medicine is provided; no licensed doctor available to answer questions after you receive your medication; spelling errors on the label or incorrect addresses for the pharmacy; and a pharmacy name on the label that you think might be fraudulent. U.S. Food and Drug Administration, 2026-09-01

One subcutaneous injection a week, on a day you choose and keep to. Your provider sets the starting dose and decides when and whether to change it; nothing about the schedule is fixed by this page.

Storage and disposal instructions come with what you are dispensed, and this page does not restate them. If anything on that label is unclear, or you have reason to doubt it, ask your provider or the pharmacy and check it against FDA's own guidance for compounded GLP-1s, cited throughout this page. A compounder's label is not the last word on it.

FDA has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide — patients measuring and self-administering incorrect doses, and in some cases health care professionals miscalculating them. U.S. Food and Drug Administration, 2026-09-01

FDA has also received adverse event reports that may relate to patients prescribed compounded semaglutide or tirzepatide in doses beyond what is in the FDA-approved label — more in a single dose, doses more often, or a faster titration schedule. Some of those events are serious. U.S. Food and Drug Administration, 2026-09-01

That heading is the regulator's, not ours. The difference is not one a patient can see on a label, so ask whoever dispenses to you which material was used.

FDA has said that semaglutide salt forms, such as semaglutide sodium and semaglutide acetate, are different active ingredients from the one used in the approved drugs, that it has no information on whether those salts share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding. U.S. Food and Drug Administration, 2026-09-01